Journals / Türk Oftalmoloji Dergisi / 2015 / Cilt: 45 - Sayı: 4

Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases

Rino-orbital Mukormikozis: Dört Olgunun Klinik Bulgu ve Tedavi Sonuçları

Pages
169–174
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With orbital involvement, surgical debridement and systemic and local treatment with antifungal agents may help avoid mutilating surgery like exenteration

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this case report, we present the clinical findings and therapeutic outcomes of four rhino-orbital mucormycosis patients.
📊
Key Findings & Data:The four patients (1 female, 3 male; age range, 55-77 years) all had diabetes mellitus and two also had chronic renal failure.
💡
Conclusion & Impact:With orbital involvement, surgical debridement and systemic and local treatment with antifungal agents may help avoid mutilating surgery like exenteration
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this case report, we present the clinical findings and therapeutic outcomes of four rhino-orbital mucormycosis patients. The four patients (1 female, 3 male; age range, 55-77 years) all had diabetes mellitus and two also had chronic renal failure. All patients exhibited proptosis, sinusitis, and dark-colored lesions on the nasopharynx and/or hard palate; three patients had ipsilateral peripheral facial paralysis. Visual acuity was no light perception in the two patients with severe orbital involvement and 0.8 in two patients with limited orbital involvement. Histopathological examination of the hard palate, nasopharynx or sinus biopsy revealed typical Mucor hyphae. Systemic liposomal amphotericin B was initiated in all patients. The patients with limited ocular involvement received amphotericin B both intravenously and by local irrigation; both patients had complete recovery. The other two patients underwent orbital exenteration; one patient died after declining systemic treatment postoperatively. Rapid diagnosis and treatment are important for the survival of rhino-orbital mucormycosis patients. With orbital involvement, surgical debridement and systemic and local treatment with antifungal agents may help avoid mutilating surgery like exenteration

Özet

Rino-orbital mukormikozis nedeniyle takip edilen hastaların bulgu ve tedavi sonuçlarını sunmak. İzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi Göz Kliniği'nde Ocak 2010-Aralık 2011 tarihleri arasında izlenen ardışık 4 hasta çalışmaya dahil edildi. Hastaların demografik verileri, klinik bulguları, tedavi yaklaşımları ve sonuçları değerlendirildi. Çalışmaya dahil edilen bir kadın, 3 erkek hastanın yaşları 57-75 yıl arasında değişmekteydi. Hastaların ikisinde kronik böbrek yetmezliği ve diabetes mellitus (DM), diğer ikisinde ise sadece DM mevcuttu. Tüm olgularda başvuru esnasında sinüzit, sert damak ve/veya nazofarinksde koyu renkli krut oluşumları ve proptozis mevcuttu. Üç olguda orbita tutulumu olan tarafta 7. sinir paralizisi izlendi. Nazofarinks, sert damak veya sinüslerden alınan biyopsilerin histopatolojik incelemesi tipik mukor hiflerini gösterdi. Tüm olgulara sistemik olarak liposomal amfoterisin B başlandı. Olguların ikisinde başvuru sırasında ışık hissi negatif olup, ağır orbita tutulumu mevcuttu. Diğer iki olguda ise görme keskinliği 0,8 düzeyinde olup, orbitaya invazyon sınırlıydı. Işık hissi negatif olan iki olguya ekzenterasyon uygulandı. Diğer iki hastaya amfoterisin B ile hem sistemik tedavi, hem de lokal irigasyon uygulandı; her iki hastada tam iyileşme sağlandı. Ekzenterasyon ve sinüs cerrahisi sonrası sistemik tedaviyi ve takibi reddeden bir hastanın kaybedildiği öğrenildi. Rino-orbital mukormikozis olgularında hızlı tanı ve tedavi hastaların yaşam şansını arttırmak açısından önemlidir. Orbita tutulumu halinde sistemik tedavi, cerrahi debridman ve antifungal ilaçlar ile lokal irigasyon uygulaması ekzenterasyon gibi mutilan bir cerrahiden kaçınılması açısından faydalı olabilir

🔖

Cite This Article

UĞURLU, Ş. K., SONGU, M., KOPAR, A., SELİM, S. (2022). Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases. Türk Oftalmoloji Dergisi, Cilt: 45 - Sayı: 4, 169–174. https://ajindex.com/articles/637971

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH,Kontoyiannis DP, Walsh TJ. Epidemiology and outcome of zygomicosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634-653
  2. Yohai RA, Bullock JD, Aziz AA, Markert RJ. Survival factors in rhino-orbitalcerebral mucormycosis. Surv Ophthalmol. 1994;39:3-22
  3. Ferguson BJ. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am. 2000;33:349-365
  4. Ferry AP, Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (Phycomycosis). A report of 16 personally observed cases. Ophthalmology. 1993;90:1096-1104
  5. Gumral R, Yildizoglu U, Saracli MA, Kaptan K, Tosun F, Yildiran ST. A case of rhinoorbital mucormycosis in a leukemic patient with a literature review from Turkey. Mycopathologia. 2011;172:397-405
  6. Turunc T, Demiroglu YZ, Aliskan H, Colakoglu S, Arslan H. Eleven cases of mucormycosis with atypical clinical manifestations in diabetic patients. Diabetes Res Clin Pract. 2008;82:203-208
  7. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21:620-625
  8. Hendrickson RG, Olshaker J, Duckett O. Rhinocerebral mucormycosis: a case of a rare, but deadly disease. J Emerg Med. 1999;17:641-645
  9. Pillsbury HC, Fischer ND. Rhinocerebral mucormycosis. Arch Otolaryngol. 1977;103:600-604
  10. Revankar SG, Hasan MS, Smith JW. Cure of disseminated zygomycosis with cerebral involvement using high dose liposomal amphotericin B and surgery. Med Mycol. 2007; 45:183-185
  11. Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect. 2009;15:87-92
  12. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother. 2003;47:3343-3344
  13. Fisher EW, Toma A, Fisher PH, Cheesman AD. Rhinocerebral mucormycosis: use of liposomal amphotericin B. J Laryngol Otol. 1991;105:575-577
  14. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K, Lass-Florl C, Bouza E, Klimko N, Gaustad P, Richardson M,Hamal P, Akova M, Meis JF, Rodriguez-Tudela JL, Roilides E, Mitrousia-Ziouva A, Petrikkos G; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of t